Pelthos Therapeutics completes merger, launches ZELSUVMI, hires 50 sales managers

Pelthos Therapeutics Inc.

Completed merger with Channel Therapeutics and closed $50.1M private placement on July 1, 2025.
Launched ZELSUVMI (berdazimer) on July 10, 2025, first at-home FDA-approved treatment for molluscum contagiosum.
Built commercial team of 90+ employees including 50 territory sales managers; early orders and prescriptions meeting/exceeding expectations.
In advanced discussions to acquire a second FDA-approved pediatric infectious disease product.
Public float ~600k shares; market cap ~$55M (~$165M fully diluted); lockup on Series A Preferred through Dec 31, 2025.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.